Newly Identified Antibody Can Be Targeted by HIV Vaccines

By Sarah Avery, Duke Health


A newly identified group of antibodies that binds to a coating of sugars on the outer shell of HIV is effective in neutralizing the virus and points to a novel vaccine approach that could also potentially be used against SARS-CoV-2 and fungal pathogens, researchers at the Duke Human Vaccine Institute report.

In a study appearing online May 20, 2021, in the journal Cell, the researchers describe an immune cell found in both monkeys and humans that produces a unique type of anti-glycan antibody. This newly described antibody has the ability to attach to the outer layer of HIV at a patch of glycans -- the chain-like structures of sugars that are on the surfaces of cells, including the outer shells of viruses. 

Read the full story here on the Duke Health website.

Give to Duke Surgery

A gift to the Department of Surgery is a gift of knowledge, discovery, and life.